Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)

(2013) J. Radford et al.   BLOOD

Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Gilles A. Salles et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Franck Andre Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Neutrophils in local and systemic antibody-dependent inflammatory and anaphylactic reactions

(2013) Friederike Jönsson et al.   JOURNAL OF LEUKOCYTE BIOLOGY

GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present

(2013) Delila J. Kern et al.   LEUKEMIA & LYMPHOMA

Neutrophils as effector cells for antibody-based immunotherapy of cancer

(2013) Marjolein van Egmond et al.   SEMINARS IN CANCER BIOLOGY

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

(2012) G. Salles et al.   BLOOD

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

(2012) L. H. Sehn et al.   BLOOD

Endocytosis of soluble immune complexes leads to their clearance by Fc RIIIB but induces neutrophil extracellular traps via Fc RIIA in vivo

(2012) K. Chen et al.   BLOOD

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab

(2012) C. A. Gerdes et al.   CLINICAL CANCER RESEARCH

Rituximab for chronic lymphocytic leukemia

(2012) Tadeusz Robak   EXPERT OPINION ON BIOLOGICAL THERAPY

Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study

(2012) Takashi Ishida et al.   JOURNAL OF CLINICAL ONCOLOGY

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

(2012) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia

(2012) Emilie Laprevotte et al.   LEUKEMIA RESEARCH

Rituximab resistance

(2011) Andrew R. Rezvani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Adam17-dependent shedding limits early neutrophil influx but does not alter early monocyte recruitment to inflammatory sites

(2011) J. Tang et al.   BLOOD

Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo

(2011) Markus Biburger et al.   IMMUNITY

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

(2011) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Structural Basis for Fc RIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes

(2011) P. A. Ramsland et al.   JOURNAL OF IMMUNOLOGY

Cell Type-Specific and Site DirectedN-Glycosylation Pattern of FcγRIIIa

(2011) Anne Zeck et al.   JOURNAL OF PROTEOME RESEARCH

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

(2011) C. Ferrara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death

(2010) J. Golay et al.   BLOOD

Cytokine-induced immune complex binding to the high-affinity IgG receptor, Fc RI, in the presence of monomeric IgG

(2010) C. E. van der Poel et al.   BLOOD

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Fcγ receptors exhibit different phagocytosis potential in human neutrophils

(2010) Selma Rivas-Fuentes et al.   CELLULAR IMMUNOLOGY

Neutrophils, from Marrow to Microbes

(2010) Niels Borregaard   IMMUNITY

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils

(2009) Mami Shibata-Koyama et al.   EXPERIMENTAL HEMATOLOGY

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

(2009) Tanja Schneider-Merck et al.   JOURNAL OF IMMUNOLOGY

Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcγRIIIb on neutrophils

(2009) Tomoaki Nakagawa et al.   LEUKEMIA RESEARCH

Glycosylation as a strategy to improve antibody-based therapeutics

(2009) Roy Jefferis   NATURE REVIEWS DRUG DISCOVERY

Neutrophil granule proteins tune monocytic cell function

(2009) Oliver Soehnlein et al.   TRENDS IN IMMUNOLOGY

Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment

(2008) G. Cartron et al.   ANNALS OF ONCOLOGY

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV

(2008) V. Minard-Colin et al.   BLOOD

The phagocytes: neutrophils and monocytes

(2008) D. C. Dale et al.   BLOOD

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

(2008) M. Peipp et al.   BLOOD

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Human Neutrophil Fcγ Receptors Initiate and Play Specialized Nonredundant Roles in Antibody-Mediated Inflammatory Diseases

(2008) Naotake Tsuboi et al.   IMMUNITY

Copy number ofFCGR3B,which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake

(2008) Lisa C. Willcocks et al.   JOURNAL OF EXPERIMENTAL MEDICINE